Table 3.
Oncologic outcomes of extraperitoneal laparoscopic radical prostatectomy (EPLRP) series.
| Rozet et al. [17] | Rassweiler et al. [18] | Paul et al. [19] | Stolzenburg et al. [20] | Tai et al. [16] | |
|---|---|---|---|---|---|
| Study period | 1998–2004 | 1999–2004 | 2000–2007 | 2001–2008 | 2004–2009 |
| No. institutions | 1 | 1 | 1 | 3 | 1 |
| No. surgeons | 4 | — | 3 | 9 | 3 |
| No. patients | 600 | 500 | 1115 | 2400 | 218 |
| Mean age (yrs) | 62 (47–73) | 64.0 (43–81) | 62.5 (42–81) | 63.3 (41–81) | 64.6 (45–82) |
| Median followup (months) | 12 | 40 | 35.6 | — | 34 |
| Mean preoperative PSA (ng/mL) | 7.4 | 11.7 (0.08–93) | 9.8 (0.8–99) | 9.8 (0.08–93) | 16.3 (0.7–185) |
| Pelvic lymph node dissection (%) | — | 83.4% | 41.6% | 50.8% | 100% |
| Pathological stage | |||||
| pT2 | 72.0% | 59.2% | 59.5% | 70.5% | 62.3% |
| pT3a | 19.2% | 21.4% | 22.4% | 19.7% | 12.4% |
| pT3b | 8.8% | 12.8% | 9% | 9.4% | 16.5% |
| pT4 | — | 3.8% | 6.9% | 0.3% | 4.2% |
| pT1-4N1 | — | 1.4% | 2.2% | — | 4.6% |
| Positive surgical margin (%) | |||||
| Overall | 17.7% | 19.0% | 26.0% | 16.0% | 27.1% |
| pT2 | 14.6% | 7.4% | 16.1% | 8.1% | 14.6% |
| pT3 | 25.6% | 31.8% | 34.6% | 35.7% | 47.9% |
| PSA recurrence-free survival rate | |||||
| 3-year | — | 83.0% | 84% | — | 82.1% |
| 5-year | — | 73.1% | 83% | — | 74.5% |